IndustryCompany release

Colospan signs first European distribution deal for CG-100 bypass device in Greece and Cyprus

EoCene Ltd. (EOCN) · Tue 10 Nov 2026

Eocene's subsidiary has granted Hospital Line SA exclusive rights to market the CE-marked CG-100 intraluminal bypass device in two Mediterranean markets.

Colospan, the wholly owned subsidiary of EoCene Ltd., signed its first European commercial distribution agreement on 10 November 2026. Under the deal, Hospital Line SA receives exclusive rights to market, sell and distribute the CG-100 in Greece and Cyprus.

CG-100 is an intraluminal bypass device that carries a CE mark. It is designed to reduce the need for diverting stomas in colorectal surgery.

The European launch is planned to run alongside the ongoing U.S. pivotal study of the device. CG-100 is not approved for commercial use in the U.S.

The summary available does not include financial terms, the length of the agreement, launch timing within the two countries or any sales targets, and none of these details can be reported here.

What it means for your team

  • Market-access teams should note that CG-100 is entering Europe through a country-by-country distributor model, starting with Greece and Cyprus.
  • Regulatory teams should keep in mind the split in status: CE-marked and commercially available in the agreed territories, but not approved for commercial use in the U.S.
  • Quality and vigilance teams at distributors handling CE-marked devices should expect post-market obligations to sit alongside the commercial launch, though no specific arrangements were disclosed here.

Company's press release (SEC filing): EoCene Ltd. ↗

Article written by VigiEye from the official source (EoCene Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →